Ocrevus (ocrelizumab)

Ocrevus (ocrelizumab) is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis (MS). It is the first approved treatment for the primary progressive form of MS.